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Summary
Continuous-flow left-ventricular assist devices (LVADs) have emerged as the stan-
dard of care for advanced heart failure patients, who require long-term mechanical 
circulatory support. In this review, we describe in brief the basics of the development 
of various devices, both the old (pulsatile-flow) and the new (continuous-flow) devices. 
A clinical review of modern devices and their today’s relevance are given in a brief 
outline.
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THE HISTORY OF THE MECHANICAL SUPPORT 
DEVICE DEVELOPMENT
Akutsu and Kolff are credited with the first reports on a successful experimental 
implantation of a total artificial heart (TAH) in 1958. Cooley used the TAH as a tem-
porary support device until transplantation in 1969. The heart performed 64 hours 
of support. In 1982, Jarvik-7 TAH was used by Dr. Jarvik as a first permanent heart 
support device. Copeland and colleagues performed the first planned TAH implant 
as a bridge-to-transplantation (BTT). After having undertaken several trials and 
multiple studies, the FDA gave an approval for HeartMate I as destination therapy 
(DT) in 2002; for TAH (CardioWest) in 2004; for HeartMate II as BTT in 2009; and for 
HeartMate II as DT in 2010 (Table 1) [1].
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THE REQUIREMENTS FOR A SUCCESSFUL MECHANICAL SUPPORT 
DEVICE
Circulatory support systems are being developed to take over the pumping fun-
ctions of the natural heart. Blood components must operate continuously, witho-
ut maintenance, for years. Mechanical components are necessarily small and must 
operate without failing under highly stressed conditions. The development of these 
highly sophisticated devices is very demanding, and only the most qualified engi-
neers are included in the process. Technologic barriers for successful Mechanical 
Circulatory Support that must be overcome are listed in Table 2.
Table 2. Technologic barriers for successful Mechanical Circulatory Support
• Development of specific materials
• Development of specific surfaces for blood-biomaterial interactions
• Blood pump designs
• Methods of storage of energy
Minimally six basic engineering disciplines are necessary for mechanical circu-
latory support system development (Table 3).
Table 3. Engineering disciplines necessary for mechanical circulatory support system 
development
 • Mechanical • Biomedical
 • Electrical • Manufacturing
 • Software • Quality engineering
The criteria for the selection of materials for mechanical support device must be 
chosen based on specific requirements for circulatory support (Table 4). [2]





A major challenge for biomedical engineers is designing cost-effective long-term 
support, which should be small, efficient, quiet and capable of continuous use for ye-
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ars of service without maintenance, while pumping blood in a hostile environment. 
The system should operate at least 5 to 10 years maintenance-free (Table 5).
The main objectives in mechanical circulatory support design are biocompa-
tibility; reliability; functionality; cost. The components of biocompatibility are the 
avoidance of the mechanical compression of vital organ or tissues; the minimizati-
on of the need for surgical dissection; the avoidance of the migration of implanted 
elements; the avoidance of the damage to formed elements in blood; the avoidance 
of the pathologic stimulation of the coagulation system; the avoidance of heat and 
electrical damage to tissue; the anatomic compatibility; the avoidance of leaching 
toxic elements to the surrounding tissue [3,4].




• Capable of continuous use for years of service without maintenance
• Capable of pumping blood in a hostile environment
• The system should operate at least 5 to 10 years maintenance-free
A SURVEY OF PULSATILE AND CONTINUOUS-FLOW PUMPS
The blood pressure and flow can be generated by either positive displacement 
(pulsatile) or rotary (turbodynamic continuous-flow) pumps (Figure 1). Positive dis-
placement (pulsatile) pumps propel fluid (blood) by cyclically changing the internal 
volume of the pumping chamber, similar to the native heart, and by moving a par-
ticular volume of blood with each ejection. The output requirement for a pulsatile 
configuration is a flow rate 5 to 10 L/min at a mean pressure of 100 to 150mmHg, and 
a rate less then 120 beats per minute.
Rotary pumps (also designated as turbodynamic) are characterized by a rota-
ting component that has one or more impellers, which are supported within the 
pump by a bearing; they are powered either through a spinning shaft or magnetic 
forces that act on magnets within the impeller. The assembly comprised of all the 
rotating elements is called the rotor of the pump.
The hydrodynamic performance of rotary pumps with axial-flow design is de-
termined by the speed of the rotor and the pressure difference across the inlet and 
the outlet orifices of the pump. As the difference decreases, blood flow through the 
pump increases with the increased speed of the pump. The relationship between 
the flow, the pump speed and the pressure is shown in Figure 2.
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Fig. 1. Pulsatile and continuous-flow Left Ventricular Assist Devices (LVADs)
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Paracorporal positive displacement ventri-
cular assist device (PVAD) (Figure 3) has been 
implanted in over 3,000 patients. It produces a 
beat rate range of 40–110 beats per minute, and a 
flow rate of 1.3 to 7.2 L/min. It is suitable for use in 
smaller patients (BSA>0.73m2) due to its external 
position. Chronic warfarin anticoagulation (In-
ternational normalized ratio INR 2.5–3.5 units) is 
required with the Thoratec pump. The PVAD is 
actuated pneumatically by the dual drive console 
for in-hospital use and portable TLC-II pneumatic 
driver for ambulatory use, either inside or outside 
the hospital. In 2003, the TLC-II was approved by 
the FDA for home discharge.
Out of 1,941 patients who had received PVAD, 
BVADs were used in 54 %, isolated LVADs in 34 
%, and RVADs in 3 % of patients. For all patients 
who were receiving PVAD assistance, the mean 
Fig. 2. The H–Q curve demonstrates the relationship between the pump speed (RPM) and the 
pressure difference across the inlet and outlet orifices of an axial-flow pump
Fig. 3. Paracorporal positive displacement ventricular 
assist device (PVAD)
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period of support was 51.8 days, and the longest time that BVAD had been implan-
ted was 3.3 years. Worldwide, survival from implant to transplantation or recovery 
was 64.8 % for patients who had BVAD, 56.6 % for patients with LVAD, and 31.2 % 
for patients with RVADs (Table 9). Five hundred patients had undergone cardioto-
my and were supported with PVADs (BVAD 31.2 %; LVAD 42.8 %; RVAD 13.4 %; in 
combination with other pumps 12.6 %). Mean PVAD support duration was 21.9 days 
(the longest duration 340 days). The survival was 44.7 %.
Fig. 4. HeartMate XVE
Fig. 5. Jarvik 2000 Left Ventricular Assist 
Device
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In the period between its first applica-
tion in 1986 and 2001, nearly 5,000 patients 
had been supported with HeartMate XVE 
(Figure 4); the survival of patients until 
transplantation or recovery was 65 %. The 
HeartMate LVAD is a positive displace-
ment pulsatile pump, which – unlike all 
the other such LVADs available – is unique, 
as its textured inner surface allows for cir-
culatory assistance without anticoagulati-
on other than antiplatelet agents [5,6].
The Jarvik 2000 Left Ventricular 
Assist Device is a miniature electrically powered axial-flow pump that provides 
continues flow from the left ventricle to the descending thoracic aorta (Figure 5). 
It is placed within the left ventricle. The 
pump’s operating range is between 8,000 
and 12,000 rpm, and it can generate a flow 
of up to 8 L/min. It can be implanted thro-
ugh a left thoracotomy, median sternoto-
my, or extrathoracically. It requires the 
application of anticoagulation dicumarol 
therapy. In the period 2000–2005, the devi-
ce has been implanted in 110 patients. The 
median period support with Jarvik 2000 
was 148±204 until BTT, and 477±544 until 
DT. The technology is associated with mi-
nimal infections and other complications, 
and it offers an optimistic option for termi-
nal and heart failure patients [7].
The Micromed – DeBakey Left Ven-
tricular Assist Device (Figure 6) is a ro-
tary pump of axial-flow design, which has 
Fig. 6. Micromed – DeBakey Left Ventricular 
Assist Device assembly
Fig. 7. Incor (Berlin Heart)
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been developed in a collaborative effort of engineers from National Aeronautics and 
Space Administration (NASA), Dr. DeBakey and Dr. George Noon, MicroMed Tech-
nology in 1996. The support was first implanted clinically in Europe in 1998, and it 
received CE Mark approval.
Fig. 9. (A) HeartMate II Schematic representation of the anatomic position and placement of 
Heart Mate II LVAS; (B) Chest radiograph demonstrating anatomic positioning of the Heart Mate 
II LVAS
Fig. 8. Diagram of an internal view of the Heart Mate II pump
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The implantation of the device requires classical surgical techniques, and anti-
coagulation therapy with dicumarol and asprine/dicumarol is required. Monitoring 
with thromboelastography is recommended. Not many postoperative complicati-
ons, like bleeding and thromboemboly, have been noted. Until 2005, the device had 
been implanted in 326 patients. The Micromed – DeBakey LVAD is specially recom-
mended with pediatric patients [8].
The Incor (Berlin Heart) LVAD is a small axial-flow pump (Figure 7). The pump 
weighs 200g and generates flows up to 7L/min. It can be used with children (Excor 
Pediatric), and clinical BTT and DT trials have reported good initial results.
The HeartMate II left ventricular assist system (LVAS) is a rotary blood pump 
with axial-flow design, and it represents the second generation of implantable assist 
devices designed to be small, more reliable devices, suitable for long-term circula-
tory support. The major advantage of this device is its axial flow, which reduces its 
size by excluding the existence of a reservoir necessary for pulsatile flow.
HeartMate II blood pump has inlet and outlet cannula and percutaneous dri-
veline, the HeartMate II system driver (computer controller) and power source (ba-
tteries). The power base unit has an alternative power source and battery charging 
system.
The internal parts of the Heartmate II pump are the titanium tube; the pump 
rotor; the rotor magnet; inlet and outlet stators with bearings and motor windings 
(Figure 8). The pump is designed for surgical implantation at the left costal margin 
below the heart and in the left pleural space (Figure 9). The inflow cannula exits in 
the left ventricle and is attached to the pump. The pump lays parallel to the diap-
hragm. The outflow cannula is tunneled back under the sternum to the ascending 
aorta. The percutaneous driveline is connected to an external system driver and a 
power source.
The anticoagulation regime is based on antiplatelet therapy (aspirin) and warfa-
rin therapy (INR 2.0–3.0) at expected therapeutical range.
HeartMate II provides excellent support in the outpatient setting as well, with 
significant improvement in functional activity, ease of use and comfort due to the 
small size of the driveline. Excellent device reliability has also been noted.
It is at the moment used as both a device for patients awaiting heart transplanta-
tion and a device for patients meeting criteria for destination therapy.
Conclusion
Axial-flow implantable devices for mechanical circulatory support had shown a 
certain advantage as a bridge-to-transplantation and, for some patients, as destina-
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tion therapy. Specialized centers with heart transplantation programs should deve-
lop a ventricular assist device program. Multidisciplinary teams participate in the 
evaluation and treatment of patients with the “end-stage” heart disease. Collecting 
all the relevant medical data, and monitoring the patients’ health and – particularly 
– quality of life should represent the major part of the program.
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Sažetak
Pregled novijih uređaja za asistirano srce i asistiranu cirkulaciju
Uređaji za asisitirano srce i asistiranu cirkulaciju postali su standard u liječenju pacijenata 
s kroničnim zatajenjem srca, kojima je neophodna dugoročna mehanička potpora srcu i cirku-
laciji. U ovom članku ukratko su opisane povijest razvoja različitih starijih (pulsatilnih) i novijih 
(kontinuirani tok) uređaja te važnost kliničke primjene ovih modernih uređaja.
Ključne riječi: asistirano srce; transplantacija srca
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